Recro Pharma Names CCO

Recro Pharma Inc., a specialty pharma company developing non-opioid therapies for pain, has appointed Fred Graff chief commercial officer. Graff brings more than 20 years' experience to Recro and started his career at Rhone Poulenc Rorer where he held various roles including director of sales, US cardiovascular division. Previously he was senior vice president of sales at Sepracor Pharmaceuticals and later he was vice president of sales at Vanda Pharmaceuticals.

Recro Pharma Inc., a specialty pharma company developing non-opioid therapies for pain, has appointed Fred Graff chief commercial officer. Graff brings more than 20 years' experience to Recro and started his career at Rhone Poulenc Rorer where he held various roles including director of sales, US cardiovascular division. Previously he was senior vice president of sales at Sepracor Pharmaceuticals and later he was vice president of sales at Vanda Pharmaceuticals.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Neurological

More from Therapy Areas

Novartis’s Cosentyx Suffers Rare Phase III Fail

 
• By 

Multi-blockbuster falls short in a giant cell arteritis study.

In Brief: 4DMT Fast-Tracks Long-Acting Wet AMD Therapy Trials, Cuts 25% Of Workforce

 

4D Molecular Therapeutics has fast-tracked its Phase III trials for 4D-150 in wet AMD, with top-line data from one now expected in H1 2027 and another underway ahead of schedule. The company is also cutting a quarter of its staff as it focuses on its late-stage pipeline and to help fund the trials.

Regeneron Wins Long-Sought FDA Nod For Lynozyfic In Myeloma

 

The agency gave accelerated approval to the BCMAxCD3-directed bispecific antibody, which had been the subject of an August 2024 CRL.